テキサスにおける免疫系とその疾患の臨床試験
テキサス内の拠点で、免疫系とその疾患に関する14件の研究が参加者を募集しています。
テキサス内の都市
公式研究テキスト（英語）
A First-in-Human Study of KK2223 in Participants With Relapsed or Refractory T Cell Non-Hodgkin Lymphoma
- The University of Texas - MD Anderson Cancer Center, Houston
被験者募集中第1相
18歳以上 · 全性別 · 2026/09/30更新 · NCT07192471A Study of JADE101 in Participants With Immunoglobulin A Nephropathy
- Jade Clinical Site, Houston
被験者募集中第2相
18歳〜60歳 · 全性別 · 2026/09/25更新 · NCT07541287A Study of Mezagitamab in Adults With Chronic Primary Immune Thrombocytopenia
- Baylor College of Medicine, Houston
被験者募集中第3相
18歳以上 · 全性別 · 2026/09/18更新 · NCT06722235Collection of Research Data and Samples From Patients Treated With Immunotherapy to Study Its Side Effects
- The Don and Sybil Harrington Cancer Center, Amarillo
- Audie L Murphy VA Hospital, San Antonio
被験者募集中観察研究
全年齢 · 全性別 · 2026/09/17更新 · NCT04242095(Apex) Bezuclastinib in Patients With Advanced Systemic Mastocytosis
- The University of Texas MD Anderson Cancer Center, Houston
被験者募集中第2相
18歳以上 · 全性別 · 2026/09/15更新 · NCT04996875A Follow-up Study of Mezagitamab in Adults With Chronic Primary Immune Thrombocytopenia
- Baylor College of Medicine, Houston
被験者募集中第3相
18歳以上 · 全性別 · 2026/09/09更新 · NCT06948318Study of Rondecabtagene Autoleucel in Aggressive Large B-Cell Lymphoma
- Baylor University Medical Center, Dallas
- Texas Transplant Institute, San Antonio
被験者募集中第1/2相
18歳以上 · 全性別 · 2026/08/25更新 · NCT05826535Open-label Extension Study of Zigakibart in Adults With IgA Nephropathy.
- Dallas Renal Group, Dallas
- Dallas Renal Group, Dallas
- Nephro Asso North Illinois Indiana, Houston
被験者募集中第3相
18歳〜100歳 · 全性別 · 2026/08/17更新 · NCT06858319Music-4-MS to Improve Cognition in People Living With Multiple Sclerosis: A Feasibility Study
- University of Texas at Austin, Austin
被験者募集中
18歳〜80歳 · 全性別 · 2026/08/17更新 · NCT07759115A Study to Evaluate the Efficacy and Safety of IMG-007 in Adult Participants With Moderate-to-Severe Atopic Dermatitis
- Inmagene Site 8, Southlake
被験者募集中第2相
18歳〜74歳 · 全性別 · 2026/08/12更新 · NCT07037901A Study of Treatment of Inflammation Before Stem Cell Transplant in People With a Primary Immune Regulatory Disorder (PIRD) and/or an Autoinflammatory Condition
- Texas Children's Hospital, Houston
被験者募集中第2相
全年齢 · 全性別 · 2026/06/02更新 · NCT05787574A Phase 1/2, Open-label, Safety and Dosing Study of Autologous CART Cells (Desmoglein 3 Chimeric Autoantibody Receptor T Cells [DSG3-CAART] or CD19-specific Chimeric Antigen Receptor T Cells [CABA-201]) in Subjects With Active, Pemphigus Vulgaris (RESET-PV)
- UT Southwestern Medical Center, Dept. of Dermatology, Dallas
- MD Anderson Texas Medical Center, Houston
被験者募集中第1/2相
18歳以上 · 全性別 · 2026/05/29更新 · NCT04422912CA-4948-101: Open-Label, Dose Escalation and Expansion Trial of Emavusertib (CA-4948) in Relapsed or Refractory Primary Central Nervous System Lymphoma (R/R PCNSL)
- The University of Texas MD Anderson Cancer Center, Houston
被験者募集中第1/2相
18歳以上 · 全性別 · 2026/04/16更新 · NCT03328078A Study to Evaluate Vimseltinib in Adults With Active Chronic Graft-Versus-Host Disease (cGVHD)
- St. David's South Austin Medical Center, Austin
- UT Southwestern Medical Center, Dallas
被験者募集中第2相
18歳以上 · 全性別 · 2025/12/15更新 · NCT06619561ClinicalTrials.govより、2026/10/05時点のデータを取得。各研究には独自の参加資格があり、参加可否は研究チームが決定します。